Details of the Drug Combination

General Information of Drug Combination (ID: DCQ8BUW)

• Drug Combination Name: Lithium Citrate + NABILONE
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Lithium Citrate (DMXAVX5): Small molecular drug
  NABILONE (DMVRYT2): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 2.13
  Bliss Independence Score: 2.13
  Loewe Additivity Score: 17.64
  LHighest Single Agent (HSA) Score: 17.64

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Lithium Citrate

Disease Entry	ICD 11	Status	REF
Bipolar disorder	6A60	Approved	[2]

Indication(s) of NABILONE

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[2]

NABILONE Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Cannabinoid receptor 2 (CB2)	TTMSFAW	CNR2_HUMAN	Inhibitor	[3]
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Inhibitor	[3]

NABILONE Interacts with 1 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cannabinoid receptor 2 (CNR2)	OTYP9P43	CNR2_HUMAN	Affects Binding	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [4] Cloning and pharmacological characterization of the dog cannabinoid CB?receptor. Eur J Pharmacol. 2011 Nov 1;669(1-3):24-31. doi: 10.1016/j.ejphar.2011.08.002. Epub 2011 Aug 19.